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Abstract
Background Paragangliomas are rare tumours derived
from the autonomic nervous system that have increas-
ingly been recognised to have a genetic predisposition.
Mutations of the enzyme succinyl dehydrogenase (SDH)
have proven to result in paraganglioma formation. There
are four subunits (A through D) that form the enzyme
complex and are associated with different genopheno-
typic expressions of disease. SDHB and SDHD muta-
tions are more common, whereas SDHA and SDHC
mutations are rare. Patients with SDHB mutations are
prone to extra-adrenal pheochromocytomas, malignant
disease and extra-paraganglial neoplasia, whereas SDHD
mutations have a greater propensity for multiple, benign
head and neck paragangliomas.
Methods Diagnosis of a sporadic paraganglioma or pheo-
chromocytoma should lead to a full genetic workup of the
patient and family if SDH mutations are found.
Results Further annual screening will be required depend-
ing on the mutation, which can have a significant impact on
radiologists and the resources of the radiology department.
Conclusion We present our imaging experience with a
series of patients with proven SDH mutations resulting in




Paragangliomas are rare tumours derived from the autonomic
nervous system. Traditionally these tumours have been
considered to be either “sporadic” or “hereditary”. Increasingly
many adrenal paragangliomas have been recognised to have a
genetic predisposition. One recently recognised genetic predis-
position relates to mutations of the enzyme succinyl dehydro-
genase (SDH). SDH is an enzyme involved in the Krebs cycle
and the production of intracellular energy. Recently discovered
mutations of the SDH enzyme have proven to result directly in
paraganglioma formation, and tumours previously thought to
be sporadic may, therefore, be hereditary. Additionally these
paragangliomas may be associated with neoplasms in other
organs. These developments in genetics have implications for
radiology with regard to screening of patients and their families
for tumours. We present our imaging experience with a series
of patients with proven SDH mutations resulting in para-
gangliomas with a review of the literature.
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Embryology
Paraganglia are aggregations of cells derived from the
neural crest. They are located throughout the body in
vascular and neuronal adventitia from the skull base to
pelvic floor [1], with the adrenal medulla being the largest
focal collection. Paraganglia are generally associated with
either the parasympathetic or sympathetic nervous system.
Although the functions of the parasympathetic and sympa-
thetic paraganglia overlap, the parasympathetic paraganglia
predominantly have a chemoreceptor function, whilst the
sympathetic paraganglia are predominantly secretory in
function. The parasympathetic paraganglia are located in
the head, neck and anterior mediastinum, whereas the
sympathetic paraganglia are located in the posterior
mediastinum and paravertebral retroperitoneum. Further
paraganglia are found around viscera such as the bladder
[2]. This functional division relates to the various SDH
subunit mutation clinical presentations.
Terminology
The term paragangliomas encompasses all neoplasms
arising from the parasympathetic and sympathetic auto-
Fig. 1 A 56-year-old female patient with a right-sided carotid
paraganglioma of the neck. Doppler ultrasound images. The para-
ganglioma appears as a homogeneous hypoechoic mass (between the
arrows). Doppler imaging reveals multidirectional hypervascularity,
which is a discerning feature of paragangliomas
Fig. 2 A 35-year-old female patient with SDHD and a right
jugulotympanic paraganglioma. a Axial CT with bone windowing
demonstrates a soft tissue lesion within the jugulotympanic fossa
causing surrounding bone erosion (arrow). b Coronal CT reformat
with bone windowing demonstrating the soft tissue mass extending
into the external auditory canal and bone erosion (arrow)
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Paragangliomas associated with the sympathetic system
are also generally secretory in nature, and historically,
those arising in the adrenal medulla have been called
pheochromocytomas, whereas those arising outside the
adrenal have been termed extra-adrenal pheochromocy-
tomas [3]. More recently, the 2004 World Health
Organisation classification of endocrine tumours defined
a pheochromocytoma as an intra-adrenal paraganglioma
and classified extra-adrenal sympathetic tumours as extra-
adrenal paragangliomas [4].
Parasympathetic paragangliomas of the head and neck
also have a number of historical names such as chemo-
dectoma and glomus tumours, but are currently referred to
by their location, e.g., carotid paraganglioma. Perhaps
confusingly, similar to the secretory sympathetic tumours
these extra-adrenal non-secretory parasympathetic lesions
are also collectively defined by the 2004 WHO classifica-
tion as extra-adrenal paragangliomas [4].
Role of SDH and genetic predisposition
Succinate dehydrogenase (SDH) is an enzyme complex
involved in the tricarboxylic acid cycle. It is also known as
mitochondrial complex II and forms part of the electron
transport train. There are four subunits (A through to D),
which form the enzyme complex. The exact pathogenetic
mechanism whereby the subunit mutations result in para-
ganglioma formation is not known [5]. It has long been
recognised that there is an increased incidence of carotid
body tumours in patients with chronic hypoxia caused by
disease or environmental factors such as living at high
altitude [5, 6]. It is, therefore, suspected that resistance to
apoptosis due to mitochondrial dysfunction and pseudo-
hypoxic drive are involved in tumourogenesis [7].
As early as the 1960s an awareness of the familial nature
of some paragangliomas emerged, and within these families
multiple tumours were commonly encountered [5]. In the
1990s Dutch researchers investigating paraganglioma fam-
ilies identified a region on chromosome 11 likely to be the
area from within which the genetic mutations resulting in
paraganglioma formation were to be found. This suscepti-
bility locus on chromosome 11 was termed the “para-
ganglioma locus 1” or PGL1 [8]. As there was a known
Fig. 4 A 60-year-old male patient with SDHB and a right-sided extra-
adrenal paraganglioma. a Contrast axial CT shows the right-sided
para-aortic paraganglioma (arrowhead), which is displacing the IVC
(arrow) anteriorly. b Methyl iodine benzyl guanidine (MIBG) scan of
the same tumour showing avid uptake (arrowhead). MIBG, either
labelled with
123Io r
131I, is a norepinephrine analogue. Sympathetic
paragangliomas are usually secretory and therefore avidly take up
MIBG as it follows the metabolic pathway of norepinephrine
Fig. 3 A 60-year-old male patient with SDHB and a right-sided
retroperitoneal paraganglioma. Coronal T2-weighted MR image
demonstrating the intermediate to high T2-weighted signal intensity
tumour enveloping the right renal artery. Note the signal voids (arrow)
in the inferior portion of the tumour in keeping with the hyper-
vascularity of the paraganglioma
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altitude [6], targeted investigation of the genes involved in
aerobic metabolism in the PGL1 locus resulted in the
discovery of the SDHD mutation [9].
Subsequent studies confirmed that SDHB and SDHC
mutations also resulted in familial paragangliomas [10, 11].
SDHA mutation, however, has at present only been
associated with metabolic neurodegenerative disorders [12].
The incidence of underlying SDH mutations in patients
with apparently sporadic parasympathetic paragangliomas
of the head and neck has been reported as high as 28% (7%
due to SDHB, 4% SDHC and 17% SDHD) [12]. The
incidence within sympathetic paragangliomas is approxi-
mately 10% (6% due to SDHB and 4% SDHD) [12].
Inheritance patterns
SDH mutations follow an autosomal dominant inheritance
pattern. SDHD mutations are also subject to genomic
imprinting of the maternal allele. Genomic imprinting of
the maternal allele means the disease only manifests if the
mutation is inherited from the father [13]. This may result
in the disease skipping generations.
Paraganglioma imaging characteristics summary
Ultrasound
Ultrasound is commonly the first imaging modality used for
investigation of neck masses. Paragangliomas of the neck
appear as homogeneously hypoechoic masses. Multidirec-
tional hypervascularity is the discerning feature on Doppler
imaging (Fig. 1)[ 14].
CT
Small paragangliomas appear as homogeneous masses,
whereas larger paragangliomas can be heterogenous in
appearance [15]. There is intense uniform enhancement
following intravenous administration of contrast agent in
keeping with the hypervascular nature of the tumour [16].
The location of the tumour aids further characterisation, e.g.
carotid body tumours cause splaying of the internal and
external carotid arteries, and jugulotympanic tumours result
in bony erosion (Fig. 2). Punctate calcification or focal
areas of high attenuation caused by acute haemorrhage may
also be seen in some tumours [17].
MRI
Paragangliomas are usually of low to intermediate signal on
T1-weighted images and intermediate to high signal on T2-
weighted images (Fig. 3). The hypervascularity results in
multiple serpentine areas of signal void [18], which results
in the characteristic “salt and pepper” appearance. The high
signal areas, or “salt”, are due to slow flow or haemorrhage,
and the low signal areas, or “pepper”, are due to the signal
voids from high flow on T1- and T2-weighted sequences
[19]. The high flow areas are better demonstrated on 3D
time of flight sequences where they show high signal
intensity [16]. As with CT, the tumours show avid
homogeneous enhancement.
SDHB presentation and tumour characteristics
The precise incidence rate of SDH mutations is unknown.
SDHB and SDHD mutations have similar prevalence and
are more common compared to SDHC, which is rare [20].
SDHB mutation more commonly results in the formation
of paragangliomas associated with the sympathetic system
[20, 21]. These are predominantly extra-adrenal paragan-
gliomas of the thorax and abdomen (Fig. 4), and less
commonly intra-adrenal paragangliomas or pheochromocy-
tomas. There is an increased risk of malignant paraganglio-
mas and metastatic disease with SDHB mutation (Fig. 5)
[21, 22]. Other than metastasis there are no specific features
of malignancy; however, rapidity of growth and surrounding
tissue invasion are suggestive. Extraparaganglial malignan-
cies such as papillary thyroid carcinoma and renal cell
carcinoma are also more prevalent in this group [20].
The age at paraganglioma diagnosis is reported at
approximately 30 years [20–22].
SDHD presentation and tumour characteristics
SDHD mutations are associated with parasympathetic
extra-adrenal paragangliomas [20, 22]. This predominantly
Fig. 5 A 42-year-old male patient with SDHB and a right-sided para-
aortic paraganglioma and a spinal metastatic lesion. Axial T2-
weighted MRI image demonstrating the right para-aortic paragan-
glioma (arrow) with intermediate T2-weighted signal intensity. The
spinal metastatic lesion (arrowhead) involves the pedicle of the
vertebra and has the same signal intensity as the primary tumour
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(Fig. 6). There is an increased chance of multifocality
(Figs. 7 and 8), but malignancy and metastatic disease are
infrequent [20, 22]. As with SDHB mutations, pheochro-
mocytomas are less common.
The age at paraganglioma diagnosis is similar to SDHB
at approximately 30 years [20, 22].
SDHB versus SDHD
Although SDHB and D mutations can be broadly divided
into the categories above, it is important to remember that
there can be overlap with tumour presentation. SDHB
mutuations can result in head and neck paraganglioma
formation, and SDHD mutations can develop thoracic and
Fig. 6 A 56-year-old female patient with SDHD and a right-sided
carotid paraganglioma of the neck; the same patient as in Fig. 1. a
Coronal T2 fat saturated MR image demonstrating the right carotid
paraganglioma (arrow) with high T2-weighted signal intensity. b
Axial T1-weighted MR image showing the paraganglioma with low
T1-weighted single intensity (arrow). Note the splaying of the internal
and external carotid arteries (arrowheads). c Gadolinium-enhanced
axial T1-weighted MR image of the tumour showing avid uniform
enhancement (arrow)
Insights Imaging (2011) 2:431–438 435Fig. 7 A 35-year-old female patient with SDHD and multiple head
and neck paragangliomas. a Coronal T1-weighted MR image
demonstrating the right jugulotympanic (arrowhead), left carotid
(open arrow) and right carotid paragangliomas (solid arrow). All three
tumours are of low to intermediate T1-weighted signal intensity. b
Coronal T2-weighted MR image demonstrating intermediate to high
signal of the right jugulotympanic (arrowhead), left carotid (open
arrow) and right carotid paragangliomas (solid arrow). c Post-
gadolinium coronal T1-weighted MR image demonstrating avid
homogeneous enhancement of the right jugulotympanic (arrowhead),
left carotid (open arrow) and right carotid paragangliomas (solid
arrow)
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mutations can result in pheochromocytoma formation. The
radiologist should be aware of this when reporting
screening investigations for these patients.
SDHA and SDHC
SDHA mutations have been described in Leigh syndrome, a
metabolic neurodegenerative disorder [24], and are not
currently recognised to result in paraganglioma formation.
SDHC mutations are rare and result in head and neck
paraganglioma formation [12]. These tumours are usually
benign and seldom multifocal [25]. Very rarely do SDHC
mutations result in pheochromocytoma formation.
SDHB and SDHD relevance
The recent advances in genetics with regards to SDH
mutations have implications for radiology. The radiological
diagnosis of a paraganglioma or pheochromocytoma should
result in a full genetic workup. Included in this is the
imaging of susceptible family members for paragangliomas
[7]. This can have a significant impact on the workload of a
radiological department. SDH mutation-positive patients
need ongoing screening as they are at high risk for
developing paragangliomas, pheochromocytomas and fur-
ther multifocal extraganglial tumours. In this context close
collaboration with the local genetics department is essential.
Following patient and family member interview and
counselling, genetic mutation can be determined from a
peripheral blood sample. The family history and type of
tumour will determine which mutation is tested for initially.
Imaging protocols
A universal approach to screening is the subject of ongoing
work. In a recent review article [12], Timmers et al.
recommended MRI of the neck, chest, abdomen and pelvis
every 1–2 years. This should be tailored according to
individual needs and the specific mutation. In cases of
SDHB mutation screening as early as 10 years of age is
recommended. Further functional imaging may also be
required along with annual history, examination and bio-
chemical testing [26]. Local imaging guidelines should be
developed in conjunction with the local genetics departments
according to imaging availability and experience. Currently
MRI of the head, neck, chest, abdomen and pelvis is the first
line investigation in our practice. Subsequent follow-up may
be performed with ultrasound or MRI. Post-treatment
imaging in our institution is determined by the nature of
the intervention on an individual patient basis.
Conclusion
SDHB and SDHD mutations result in paraganglioma
formation. Whereas SDHB patients are prone to extra-
adrenal pheochromocytomas, malignant disease and extra-
paraganglial neoplasia, SDHD mutations have a greater
propensity for multiple, benign head and neck paraganglio-
mas. Diagnosis of a sporadic paraganglioma or pheochro-
mocytoma should lead to a full genetic workup of the
patient and family if SDH mutations are found. SDH
mutation-positive family members should be placed on
annual screening depending on the mutation. MRI of the
neck, chest, abdomen and pelvis is the initial screening
practice in our department. These mutations can therefore
have a significant impact on radiologists and the resources
of the radiology department.
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